Sialix Inc. revealed on Tuesday that it closed a financing agreement worth US $1 million with investors that include Mass Medic Angels, Maine Angels, Boston Harbor and Launchpad. The additional fund will go to its research on medicines to treat cancer and other diseases, the statement said.
Jeff Behrens, president of Sialix, said they welcome all investors who share their vision on the pioneering work to research on the impact of glycans in cancer as well as "inflammatory mediated diseases."
Representatives of the new investors have joined Sialix Board of Directors as an offshoot of the agreement.
In explaining their investment, Brad Curley, Boston Harbor Angels member, said they were intrigued by the prospects of commercializing cancer treatment and other nutritional products. He said that the initial research of Sialix showed a lot of promise.
"As a Board member, I look forward to taking part in the company's progress as these products move through the development process," he said.
Join the Conversation